Influence of tumours on normal cells and optimal chemotherapy regimens: The case of several drugs and toxicity constraints

Mathematical Medicine and Biology

Volumn 22, Issue 2, 2005, Pages 143-162

  Matveev, Alexey S ^a   Savkin, Andrey V ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Influence of tumours on normal cells; Optimal chemotherapy regimen

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; CHEMOTHERAPY;

CANCER CHEMOTHERAPY; CELL POPULATIONS; CELL-BE; CELL/B.E; CELL/BE; CERTAIN HYPOTHESIS; FIXED PERIOD; INFLUENCE OF TUMOR ON NORMAL CELL; INHIBITING EFFECT; OPTIMAL CHEMOTHERAPY REGIMEN;

TUMORS;

ANTINEOPLASTIC AGENT; HEMOPOIETIC GROWTH FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL COUNT; CELL GROWTH; CELL POPULATION; DRUG TOXICITY; MATHEMATICAL MODEL; OPTIMAL DRUG DOSE; PHARMACOLOGICAL PARAMETERS; PRESCRIPTION; PROCESS OPTIMIZATION; TUMOR; BIOLOGICAL MODEL; DRUG ADMINISTRATION; HUMAN; NEOPLASM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 25144497567     PISSN: 14778599     EISSN: 14778602     Source Type: Journal    
DOI: 10.1093/imammb/dqi004     Document Type: Article

References (41)

1. Afenya, E. (1996) Acute leukemia and chemotherapy: A modelling viewpoint. Math. Biosci., 138, 79-100.
2. Afenya, E. (2001) Recovery of normal hemopoiesis in disseminated cancer therapy - a model. Math. Biosci., 172, 15-32.
3. Afenya, E. & Bentil, D. (1998) Some perspectives on modelling leukemia. Math. Biosci., 150, 113-130.
4. Afenya, E. & Calderón, C. (1996) Normal cell decline and inhibition in acute leukemia: A biomathematical modeling approach. J. Can. Det. Prev., 20, 171.
5. Afenya, E. & Calderón, C. (1999) A remark on leukemogenesis. Int. J. Math. Stat. Sci., 8, 199.
6. Afenya, E. & Calderón, C. (2000) Diverse ideas on the growth kinetics of dessiminated cancer cells. Bull. Math. Biol., 62, 527-542.
7. Barbolosi, D. & Iliadis, A. (2000) Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model. Comput. Biomed. Res., 33, 211-226.
8. Barbolosi, D. & Iliadis, A. (2001) Optimizing drug regimens in cancer chemotherapy: A simulation study using PK-PD model. Comput. Biol. Med., 31, 157-172.
9. Boldrini, J. & Costa, M. (2000) Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy. IMA J. Math. Appl. Med. Biol., 17, 33-51.
10. Clarke, F. (1983) Optimization and Nonsmooth Analysis. New York: Wiley.
11. Clarkson, B. (1972) Acute myelocytic leukemia in adults. Cancer, 30, 1572-1582.
12. Clarkson, B., Ohkita, T., Ota, K. & Fried, J. (1967) Studies of cellular proliferation in human leukemia. I. Estimation of growth rates of leukemic and normal hematopoietic cells in two adults with acute leukemia given single injection of tritiated thymidine. J. Clin. Investig., 46, 506-529.
13. Costa, M., Boldrini, J. & Bassanezi, R. (1992) Optimal chemical control of populations developing drug resistance. IMA J. Math. Appl. Med. Biol., 9, 215-226.
14. Costa, M., Boldrini, J. & Bassanezi, R. (1994) Optimal chemotherapy: A case study with drug resistance, saturation effect, and toxicity. IMA J. Math. Appl. Med. Biol., 11, 45-59.
15. Costa, M., Boldrini, J. & Bassanezi, R. (1995a) Chemotherapeutic treatments involving drug resistance and level of normal cells as a criterion of toxicity. Math. Biosci., 125, 191-209.
16. Costa, M., Boldrini, J. & Bassanezi, R. (1995b) Drug kinetics and drug resistance in optimal chemotherapy. Math. Biosci., 125, 191-209.
17. Dancey, J., Deubelbeiss, K., Harker, L. & Finch, C. (1976) Neurophil kinetics in man. J. Clin. Investig., 58, 705-715.
18. Dibrov, B., Zhabotinsky, A., Neyfakh, Y., Orlova, M. & Churikova, L. (1985) Mathematical model of cancer chemotherapy. Periodic schedules of phase-specific cytotoxic-agent administration increasing the selectivity of therapy. Math. Biosci., 73, 1-31.
19. Dubovickij, A. & Milutin, A. (1971) Necessary Conditions for a Weak Extremum in a General Optimal Control Problem. Moscow: Nauka. (In Russian.)
20. Eisen, M. (1979) Mathematical Models in Cell Biology and Cancer Chemotherapy. Lecture Notes in Biomathematics, vol. 30. New York: Springer.
21. Fister, K. & Panetta, J. (2000) Optimal control applied to cell-cycle-specific cancer chemotherapy. SIAM J. Appl. Math., 60, 1059-1072.
22. Hille, E. (1969) Lectures on Ordinary Differential Equations. London: Addison-Wesley Publishers.
23. Iwao, N., Yoshida, M., Hatake, K., Hoshino, Y., Hagiwara, S., Tomizuka, H., Shimizu, R., Suzuki, T. & Furukawa, Y. (1995) Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: A pilot study. Leukemia Res., 19, 899-903.
24. Keating, M., Eastey, E., O'Brien, S., Kantarjian, H., Robertson, L. & Plunket, W. (1994) Clinical experience with fludarabine in leukaemia. Drugs, 47, 39-57.
25. Kirk, D. (1970) Optimal Control Theory. An Introduction. Englewood Cliffs, NJ: Prentice Hall.
26. Lee, E. & Markus, L. (1967) Foundations of Optimal Control Theory. New York: Wiley.
27. Martin, R. & Teo, K. (1994) Optimal Drug Administration in Cancer Chemotherapy. Singapore: World Scientific.
28. Matveev, A. & Savkin, A. (2001) Optimal chemotherapy regimens: Influence of tumors on normal cells and several toxicity constraints. IMA J. Math. Appl. Med. Biol., 18, 25-40.
29. Matveev, A. & Savkin, A. (2002) Application of optimal control theory to analysis of cancer chemotherapy regimens. Syst. Control Lett., 46, 311-321.
30. Murray, J. (1990) Optimal control for a cancer chemotherapy problem with general growth and loss functions. Math. Biosci., 98, 273-287.
31. Murray, J. (1994) Optimal drug regimens in cancer chemotherapy for single drugs with block progression through the cell cycle. Math. Biosci., 123, 183-213.
32. Panetta, J. (1997) A mathematical model of breast and ovarian cancer treated with paclitaxel. Math. Biosci., 146, 89-113.
33. Rubinov, S. & Lebowitz, J. (1975) A mathematical model of neutrophil production and control in normal man. J. Math. Biol., 1, 187-225.
34. Rubinov, S. & Lebowitz, J. (1976a) A mathematical model of the acute myeloblastic leukemic state in man. Biophys. J., 16, 897-910.
35. Rubinov, S. & Lebowitz, J. (1976b) A mathematical model of the chemotherapeutic treatment of acute myeloblastic leukemia. Biophys. J., 16, 1257-1271.
36. Schrier, S. (1988) Hematopoiesis and red blood cell function, Sci. Am. Med., 1, 2-31.
37. Schrier, S. (1994) The leukemias and the myeloproliferative disorders, Sci. Am. Med., 8, 1-27.
38. Swan, G. (1984) Application of optimal Control Theory in Biomedicine. New York: Marcel Decker.
39. Swan, G. (1990) Role of optimal control theory in cancer chemotherapy. Math. Biosci., 101, 237-284.
40. Swierniak, A., Polanski, A. & Kimmel, M. (1996) Optimal control problems arising in cell-cycle-specific cancer chemotherapy. Cell Prolif., 29, 117-139.
41. Zietz, S. & Nicolini, C. (1979) Mathematical approaches to optimization of cancer chemotherapy. Bull. Math. Biol., 41, 305-324.